Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Hearing and Speech Science, Vanderbilt Bill Wilkerson Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Otolaryngol Head Neck Surg. 2023 Dec;169(6):1615-1623. doi: 10.1002/ohn.375. Epub 2023 May 26.
Cochlear implants (CIs) for single-sided deafness (SSD) have only been approved for patients 5 years and older despite data supporting that younger children can also benefit from implantation. This study describes our institution's experience with CI for SSD in children 5 years and younger.
Case series with chart review.
Tertiary referral center.
A case series with chart review identified 19 patients up to age 5 years who underwent CI for SSD between 2014 and 2022. Baseline characteristics, perioperative complications, device usage, and speech outcomes were collected.
The median age at CI was 2.8 (range, 1.0-5.4) years, with 15 (79%) patients being below age 5 at implantation. Etiologies of hearing loss were idiopathic (n = 8), cytomegalovirus (n = 4), enlarged vestibular aqueduct (n = 3), hypoplastic cochlear nerve (n = 3), and meningitis (n = 1). The median preoperative pure-tone average was 90 (range, 75-120) and 20 (range, 5-35) dB eHL in the poor and better hearing ears, respectively. No patients had postoperative complications. Twelve patients achieved consistent device use (average, 9 h/d). Three of the seven who were not consistent users had hypoplastic cochlear nerves and/or developmental delays. The three patients with available preoperative and postoperative speech testing showed significant benefits, and five patients with available postoperative testing demonstrated speech recognition in the implanted ear when isolated from the better ear.
CI can safely be performed in younger children with SSD. Patients and families accept early implantation, as evidenced by consistent device use, and derive notable benefits in speech recognition. Candidacy can be broadened to include SSD patients under age five years, particularly individuals without hypoplastic cochlear nerves or developmental delay.
尽管有数据表明,较小的儿童也能从植入物中受益,但单侧聋(SSD)的耳蜗植入物仅批准用于 5 岁及以上的患者。本研究描述了我们机构在 5 岁及以下单侧聋儿童中进行耳蜗植入的经验。
病例系列,结合图表回顾。
三级转诊中心。
通过病例系列和图表回顾,确定了 19 名患者在 2014 年至 2022 年间因 SSD 接受了 CI。收集了基线特征、围手术期并发症、设备使用和言语结果。
CI 的中位年龄为 2.8 岁(范围为 1.0-5.4 岁),15 名(79%)患者在植入时年龄小于 5 岁。听力损失的病因包括特发性(n=8)、巨细胞病毒(n=4)、扩大的前庭水管(n=3)、发育不良的耳蜗神经(n=3)和脑膜炎(n=1)。术前纯音平均听力为 90 分贝(范围为 75-120 分贝)和 20 分贝(范围为 5-35 分贝),分别为差耳和较好耳。无术后并发症患者。12 名患者实现了持续的设备使用(平均每天 9 小时)。7 名非持续使用者中有 3 名患有发育不良的耳蜗神经和/或发育迟缓。3 名术前和术后均有言语测试的患者获益显著,5 名术后测试的患者在植入耳与好耳分离时,言语识别能力显著提高。
SSD 儿童可安全地进行 CI。患者及其家属接受早期植入,表现为持续的设备使用,并在言语识别方面获得显著收益。对于年龄小于五岁、特别是没有发育不良的耳蜗神经或发育迟缓的 SSD 患者,候选资格可以扩大。